medigraphic.com
Centro Universitario de Ciencias de la Salud de la Universidad de Guadalajara y del OPD Hospitales Civiles de Guadalajara

2007, Number 3

<< Back Next >>

Inv Salud 2007; 9 (3)

Mechanism of cellular injury in neurodegenerative diseases

Sánchez ES, Ramírez MAE, Vázquez LLS, Cabrales BBI, Domínguez HMA, González HME

Language: Spanish
References: 56
Page: 205-213
PDF size: 294.49 Kb.


ABSTRACT

Neurodegenerative disorders are chronic and progressive diseases caused by genetic and environmental factors.
The clinical manifestations are dependent on the affected area on the Central Nervous System. Several etiologic factors which include encephalic metabolic derangements, central insulin resistance, oxidative stress, inflammatory process, prions and xenobiotics are involved.
Besides these factors, gene mutations are related to Alzheimer disease; Parkinson disease, amyotrophic lateral sclerosis and muscular-spinal atrophy have been found. In Huntington disease, cerebellar-spinal ataxias, Friedreich´s ataxia and muscular-spinal-bulbar atrophy, excessive repeats of 3 to 5 nucleotides fragments have been detected.
These neurological disorders have in common production and accumulation of aberrant proteins with abnormal metabolism, which conduce to selective neuronal death probably by apoptosis.


REFERENCES

  1. Martin JB. “Molecular basis of the neurodegenerative disorders”. N EnJ Med 1999; 340:1970-1980

  2. Friedlander RM.”Apoptosis and caspases in neurodegenerative diseases”. N Engl J Med 2003; 348: 1365-75.

  3. Wishart T, Parson S, Gillingwater T.” Synaptic Vulnerability in Neurodegenerative Disease”. J Neuropathol Exp Neurol 2006:65, number 8.

  4. Guzmán-López A, Montes-Recinas S, Espinosa B, Centeno E, Rembao D, Sánchez A.”Localización ultraestructural de residuos glicosilados en las células de Purkinje en la enfermedad de Huntington”. Arch neurocien (Mex)2001; suplemento: 2-3.

  5. Bossy-Wetzell E, Schwarzenbacher R, Lipton SA. “Molecular pathways to Neurodegeneration”. Nat Med 2004.supplement July: S2-S9.

  6. Weiner W.J., Singer C., Shulman L.M., Bennett D. A., Goetz C. G.Evans D. A.” Parkinsonism and Parkinson‘s Disease”. Eur J Hum Genet 2004; 334:1611-1612.

  7. Rowland-Lewis P, Shneider NA. “Amyotrophic Lateral Sclerosis”. N Engl J Med 2001; 344:1688-1700.

  8. Ochoa-Morales A, Alonso-Villatela ME. “Ataxia: efectos psicosociales”. Arch Neurocien (Mex) 2001; 6: 108-11.

  9. Rasmussen A, Yescas P, Matsura T, Ruano L, Ochoa A, Ashizawa T, et al. “Caracterización clínica y molecular de un nuevo tipo de ataxiaautosómica dominante: ataxia espinocerebelosa tipo 10 (SCA10)”. Arch-Neurocien (Mex) 2001; suplemento: 23-4.

  10. Ruíz-Sandoval JL, Otero-Siliceo. “Aspectos bioquímicos de la enfermedad de Alzheimer”. Arch Neurocien (Mex)1997; 2: 86-97.

  11. Jeffrey L .”Alzheimer disease”. JAMA 2002; 287: 2335-8.

  12. Nussbaum RL, Ellis CE. “Alzheimer´s disease and parkinson´s disease”. N Engl J Med 2003; 348: 1356-64

  13. Cabrera-Gómez JA, López-Saura P. “Interferón alfa y enfermedad de Alzheimer”. Arch Neurocien (Mex); 5: 65-73.

  14. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, et al. Lipidation of apolipoprotein E influences its isoform-especific interaction with Alzheimer´s amyloid á peptides. Biochem J 2000; 348: 359-65.

  15. Andersen JK. “Oxidative stress in neurodegeneration: cause or consequense?”. Nat Med 2004. supplement July: S18-S25.

  16. Edison P, Archer A, Hinz R, Hammers A, Pavese N, Tay Y, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks D. “Amyloid, hypometabolism, and congnition in Alzheimer Disease: an (11C)PIB and(18F)FDG PET study”. Neurology 2007;68;501-508.

  17. Koo EH, Kopan R.” Potencial role of presenilin-regulated signaling pathways in sporadic neurodegeneration”. Nat Med 2004. supplementJuly: S26-S33.

  18. Ross CA, Poirier MA. “Protein aggregation and neuro-degenerative Diseases”. Nat Med 2004. supplement July: S10-S17.

  19. Santagata D, Fulga T, Duttaroy A, Feany M, et al.” Oxidative stress mediates tau-induced neurodegeneration in Drosophila”. J Clin Invest 2007;1:117:236-45.

  20. Infante-Velázquez EJ, Pérez Del Campo YH, Díaz-Pérez MJ, Barnet-Domínguez JA, Ortega-Pérez MA.” Las tautopatías”. Rev Mex Neuroceni 2002; 3: 165-67.

  21. Mena-López R, García-Sierra F. “ Bases neuropatológicas y moleculares de la enfermedad de Alzheimer”. Arch Neurocien (Mex) 1998; 2:164-73.

  22. Sánchez-Corona J, Flores-Martínez SE, Gallegos Arreola MP. “Aspectos genéticos de las enfermedades neurodegenerativas”. Arch Neurocien (Mex) 1998; 3: 160-3.

  23. Corona-Vázquez T. “Las enfermedades neurológicas, su dimensión y repercusión social”. Gac Med Mex 2002; 138: 533-5.

  24. Velásquez-Pérez L, Alonso-Vilatela ME, Yescas-Gómez P, Guerrero-Camacho J, Rodríguez Agudelo Yaneth, Quijano-Martinez MC, et al. “Frecuencias, determinación de la ApoE y otros factores asociados a la enfermedad de Alzheimer en pacientes atendidos en el INNN Manuel Velasco Suárez”. Arch Neurocien (Mex) 2000; suplemento: 6-7.

  25. Prusiner SB. “Neurodegenerative diseases and prions”. N Engl J Med 2001; 344: 1516-26.

  26. Asanuma M, Miyazaki I, Ogawa N. “Neuroprotective effects of nonsteroidalanti-inflamatory drugs on neurodegenerative diseases”. Curr Pharm Des 2004; 10: 695-700

  27. Soto C, Castilla J. “The controversial protein-only hypothesis of prion Propagation”. Nat Med 2004. supplement July: S63-S67.

  28. Tornero D, Ceña V, González-García C, Jordan J. “Papel del poro de permebealidad transitoria mitocondrial en los procesos neurodegenerativos”. Rev Neurol 2002; 35: 354-361.

  29. Jordán J, Galindo MF, Ceña V, González García C. “Cisteína proteasa y neurodegeneración”. Rev Neurol 2000; 34: 333-40.

  30. Waldmeier PC, Tatton WG. “Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?”. Drug Discov Today 2004. 9: 210-8.

  31. Boje KM. “Nitric oxide neurotoxicity in neurodegenerative diseases”. Front Biosci 2004. 9: 763-76

  32. Emerit J, Edeas M, Bricaire F. “Neurodegenerative diseases and oxidative Stress”. Biomed Pharmacother 2004; 58:39-46.

  33. DiMauro S, Schon EA. “Mitochondrial respiratory-Chain diseases”. N Engl J Med 2003; 348: 2656-68.

  34. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al.” Role for neuronal insulin resistence in neuro-degenerative diseases”. Proc Natl Acad Sci USA 2004;101 3100-5.

  35. Beyer K, Humert J, Ferrer A, Lao J, Carrato C, López D, Ferrer I, Ariza A. “Low Alpha-Synuclein 123 mRNA levels in dementia with Lewy bodies and Alzheimer disease”. Neuro Report Vol 17 No 12 21 August 2006.

  36. Jiménez-Jiménez FJ, Pilés-Galdón S, Muñoz-Farjas E, Aguilar-Barberá M. “Síndromes parkinsonianos”. Arch neurocien (Mex) 2000; 5: 84-95.

  37. Alonso-Villatela ME, Ochoa A, Ruíz-López I. “Enfermedad de Huntigton”. Arch Neurocien (Mex) 1998; 3: 38-46.

  38. Rosenberg RN. “DNA-Triplet Repeats and Neurologic Disease” (ed). N Engl J Med 1996; 335:1222-1224.

  39. Gómez A, Alegret M, Muñoz E, Sainz A, Monte G y tolosa E. “Decreased frontal choline and neuropsychological performance in preclinical Huntington disease”. Neurology 2007;68;906-910.

  40. Ruíz-López I, Alonso-Villatela ME, Rodríguez-Agudelo Y, Ochoa- Morales A, Díaz-Olavarrieta C, Martínez-Aranda C, et al. “El papel del psiquiatra en el diagnóstico predictivo de la enfermedad de Huntigton”. Arch Neurocien (Mex) 1997; 2: 167-70.

  41. Villa M, Przedborski S. “Genetic clues to the pathogenesis of Parkinson’s Disease”. Nat Med 2004.supplement July: S58-S62.

  42. Samii A, Nutt JG, Ransom BR. “Parkinson’s disease”. Lancet 2004; 363: 1783-93.

  43. Colín-Barenque L, Avila-Costa MR, Espinosa-Villanueva J, Manchado- Salas J. “Análisis ultraestructural comparativo en pacientes con enfermedad de Parkinson y ratas viejas”. Arch neurocien (Mex) 2000; 5: 168-73.

  44. Lang A, “The Progression of Parkinson Disease A hypotesis”. Neurology 2007;68:948-952.

  45. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. “The new mutation E46K of alpha-synuclein causes Parkinson and Lewy body dementia”. Ann Neurol 2004;55: 164-73.

  46. Rasmussen A, Yescas P, Matsura T, Ochoa A, Ashizawa T, Guerrero J, et al. “Diagnóstico molecular de ataxia espinocerebelosa 1 y 2 (SCA1 y SCA2) en el INNN”. Arch Neurocien (Mex) 2000; suplemento: 19-20.

  47. Martin L, “Mitochondriopathy in Parkinson Disease and Amyotrophic Lateral Sclerosis”. J Neuropathol Exp Neurol Vol. 65, No. 12, December 2006, pp 1103-1110.

  48. Boll-Woehrlen MC, Murillo-Bonilla LM, Montes S, Zubeldía-Alcaraz M, Ríos-Castañeda C. “Nitritos, nitratos y actividad SOD en el LCR de pacientes con esclerosis lateral amiotrófica”. Arch Neurocien (Mex) 2001; suplemento: 4-5.

  49. Hafezparast M, Ahmad-Annuar A, Hummerich H, Shah P, Ford M, Baker C, et al. “The paradigms for the identification of new genes in motor neuron degeneration. Amyotroph Lateral Scler Other Motor Neuron Disord” 2003; 4: 249-57.

  50. Nakano T, Nakaso K, Nakashima K, Ohama E. “Expression of ubiquitin-binding protein p62 in ubiquitin-immunoreactive intraneuronal inclusions in amyotrphic lateral sclerosis with dementia:analysis of five autopsy cases with broad clinico-pathological spectrum”. Acta Neurophatol (Berl)2004;334:359-64.

  51. Reinstein E, Clechanover A. Narrative Review: “Protein Degradation and Human Diseases: The Ubiquitin Connection”. Ann Intern Med. 2006;145:676-684.

  52. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S. “Glutamate receptors: RNA editing and death of motor neurons”. Nature 2004; 427: 801.

  53. Finsterer J, Stollberger C. “Cardiac involvement in Werdnig-Hoffmann’s spinal muscular atrophy”. Cardiology 1999; 92:178-82.

  54. Boda B, Mas C, Giudicelli C, Nepote V, Guimiot F, Levacher B, et al. “Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells”. Eur J Hum Genet.2004[Epub ahead of print].

  55. Mariotti C, Castellotti B, Pareyson D, Testa D, Eoli M, Antozzi C, et al. “Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families”. Neuromuscul Disord 2000;10:391-7.

  56. Jinnai K, Nishimoto K, Itoh K, Hashimoto K, Takahashi K.” Association of spinal and bulbar muscular atrophy with myotonic dystrophy type 1”. Muscle Nerve 2004 ;29:729-33.




2020     |     www.medigraphic.com